Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Orezone Announces More Drilling Results at Bomboré Project Outside of Existing Mining Permit and Qualified Resources

2018-07-16 globenewswire
OTTAWA, July 16, 2018 (GLOBE NEWSWIRE) -- Orezone Gold Corporation (TSXV:ORE) (“Orezone” or the “Company”) is pleased to report recent Reverse Circulation (“RC”) and Diamond Drilling (“DD”) drilling results from several target areas that lie outside of the main Bomboré deposit mining permit. This programme totalled 55 RC boreholes (2,904 m) and 34 DD boreholes (4,916.5 m) that were drilled during Q1 2018.
ORZCF ORE

1
Orezone Gold: The Updated Feasibility Study Looks Promising, Is A Takeover Now In The Cards?

2018-07-13 seekingalpha
Orezone just released an Updated Feasibility Study highlighting their Bomboré project as possessing: strong economics, modest CapEx, quick payback, simple mine plan, and ample remaining development/exploration upside potential.
ORZCF WFRSF BTG WAF EDVVF EDVMF EVR OCR EDV ORE

0
Orezone Announces Positive Feasibility Study for the Bomboré Gold Project

2018-07-09 globenewswire
OTTAWA, July 09, 2018 (GLOBE NEWSWIRE) -- Orezone Gold Corporation (TSXV:ORE) (“Orezone” or the “Company”) is pleased to announce the summary results of an updated independent Feasibility Study (the “FS”) for its 90%-owned Bomboré Gold Project in Burkina Faso, West Africa. All reported figures are in U.S. dollars and are on a 100% project basis unless otherwise stated.
ORZCF MALRY MALRF MIN ORE

0
Orezone Gold Closes C$44.92 Million Private Placement

2018-04-10 globenewswire
OTTAWA, April 10, 2018 (GLOBE NEWSWIRE) -- Orezone Gold Corporation (TSX-V:ORE) (“Orezone” or the “Company”) is pleased to announce that it has closed its non-brokered private placement (the “Offering”) previously-announced on March 26, 2018. The Company has sold 56,150,000 common shares of the Company (“Common Shares”) at a price of C$0.80 per share for gross proceeds of C$44,920,000. The Common Shares issued pursuant to the Offering will be subject to a four month hold period expiring on August 10, 2018.
ORZCF ORE

0
BRIEF-Resource Capital Fund VII announces acquisition Of 19.99 pct of Orezone Gold Corp shares

2018-04-10 reuters
* RESOURCE CAPITAL FUND VII L.P. ANNOUNCES ACQUISITION OF 19.99% OF SHARES OF OREZONE GOLD CORPORATION
ORZCF ORE

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 68616T109